Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and ctDNA in Metastatic Non-squamous NSCLC
NCT02955758Phase 2Completed
- Sponsor
- Joel Neal
- Start
- Oct 2016
- Primary completion
- Apr 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by Joel Neal. Primary endpoint: Correlation of Tumor-informed CAPP-Seq ctDNA Analysis With Radiologic Tumor Assessments up to 2 years. Started Oct 2016; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02955758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02955758.